Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Knight Therapeutics gets $125mm by selling priority review voucher to Gilead

Executive Summary

Knight Therapeutics Inc., a Paladin Labs spec pharma spin-off, raised $125mm in cash by selling its neglected tropical disease priority review voucher (PRV) to Gilead Sciences Inc. Knight put the PRV up for sale in March 2014.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Other

Related Companies

Advertisement
UsernamePublicRestriction

Register